FLT3 and acute myeloid leukemia: A highly selective, 2nd generation oral FLT3 type I inhibitor with activity against both FLT3 mutation subtypes (ITD and TKD) and weak activity against c-Kit, Gilteritinib (117) has been approved by EMA for treatment of relapsed/refractory AML with FLT3-ITD or TKD mutations, on the basis of the results of a phase III trial (118).